Effects Of Quetiapine Administration On Peripheral PDLIM5 MRNA Expression In Bipolar Depression Disorder

Background: Bipolar disorder is a highly prevalent psychiatric disorder in the clinic.It is characterized by high mood and alternating depression.Depressive episodes are more common than manic episodes and hypomania.Current pharmacological treatments for bipolar depression include the use of antidepressants,lithium salts,atypical antipsychotics(such as quetiapine and olanzapine)and anticonvulsants(such as valproate,lamotrigine).Numerous studies have shown that PDLIM5 plays an important role in mediating the pathogenesis of bipolar depression.However,there is no clear study to show whether the change in the expression of PDLIM5 in patients with bipolar depression is caused by the specific pharmacological effects of drugs.Objective: The main purpose of this study was to investigate whether quetiapine treatment bipolar depression disorder affects expression pattern of PDLIM5 in peripheral blood.Methods: The Montgomery and Asperger Depression Rating Scale(MADRS)was used to assess the severity of depressive symptoms in patients with bipolar depression before and after quetiapine treatment,and measured the expression of PDLIM5 mRNA in patients using quantitative real-time PCR.Results: There was a significant reduction of depression symptoms after quetiapine treatment(P<0.0001).PDLIM5 mRNA levels in peripheral blood were significantly lower in patients with untreated depressive disorder than in healthy controls(P= 0.0035)and increased after 8 weeks of quetiapine treatment(P = 0.039).The PDLIM5 mRNA levels in peripheral blood were not affected by quetiapine treatment and not related to clinical respons(P>0.05).Conclusion: Quetiapine can effectively improve the depressive symptoms of patients with bipolar depression,but does not affect the expression of PDLIM5 in peripheral blood.